<DOC>
	<DOCNO>NCT02411526</DOCNO>
	<brief_summary>This open-label , multiple dose , PK safety study patient chronic , stable schizophrenia schizoaffective disorder .</brief_summary>
	<brief_title>Safety PK Trial With Injectable ZX003 ( Risperidone-SABER® ) Compared Risperdal® Consta® Stable Schizophrenia</brief_title>
	<detailed_description>Approximately 75 male female patient schizophrenia schizoaffective disorder antipsychotic maintenance medication enrol study . There 4 plan cohort 14 patient per cohort . In Cohorts 1-3 , patient ' plan participation study total approximately 22 week , include Screening period 35 day , study treatment period 120 day ( include follow-up ) . In Cohort 4 plan participation study total approximately 18 week include Screening period 35 day study treatment 92 day ( include follow-up ) .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>1 . Male female patient 18 60 year age , inclusive . 2 . Diagnosis schizophrenia , schizoaffective disorder per DSMV criterion past 6 month , dependent diagnosis . 3 . Currently maintenance antipsychotic medication ( ie , patient treat antipsychotic medication stable dose 4 week prior Screening psychosisrelated dose change 8 week prior Screening ) . 4 . Body Mass Index ( BMI ) ≥20 ≤40 kg/m2 . 5 . Female patient nonchildbearing potential ( surgically sterile [ hysterectomy ] ) postmenopausal ≥2 year ; nonpregnant , nonlactating female childbearing potential agree use medically acceptable form birth control ( hormonal contraception , abstinence , diaphragm spermicide , condom spermicide , intrauterine device ) Screening EndofStudy visit . 6 . No clinically significant abnormal laboratory value . 7 . No clinically significant finding 12lead ECG . 8 . No clinically significant finding vital sign measurement . 9 . Be inform nature study give write consent prior initiate study procedure . 1 . Unwilling provide genotyping ( phenotyping ) sample CYP2D6 . 2 . Have know suspected carcinoma . 3 . Have know presence history renal hepatic insufficiency . 4 . Have know history , hypersensitivity clinically significant idiosyncratic reaction risperidone , paliperidone , and/or drug substance similar activity . 5 . Have history alcohol drugdependence per DSMV criterion 6month period immediately prior Screening . 6 . Have history epilepsy risk seizure . 7 . Are pregnant , lactating , likely become pregnant study . 8 . Have take antipsychotic depot product ( include investigational product ) within 60 day prior Screening . 9 . Participated another clinical trial receive investigational product within 30 day prior Screening . 10 . Have positive alcohol breathalyzer test Screening Admission . 11 . Have positive Screening test hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) , human immunodeficiency virus ( HIV ) . 12 . Have positive urine drug test ( cocaine , amphetamine , barbiturate , opiate , benzodiazepine ( unless prescribe ) , cannabinoids , etc . ) Screening Admission . 13 . Excessive use caffeinecontaining beverage exceed 500 mg caffeine/day ( 5 cup coffee ) . 14 . Use alcohol alcoholcontaining food , medication beverage , within 48 hour prior Admission . 15 . Excessive smoking , define smoke 2 pack cigarette ( 5 cigar ) per day 1 year great . 16 . Donation blood ( &gt; 500 mL ) blood product within 2 month ( 56 day ) prior Admission . 17 . Have use concomitant medication significantly impact CYP2D6 ( moderate strong inducers/inhibitors ) , within 14 day 5 halflives ( whichever longer ) prior Admission . Medications judge interact risperidone may continue discretion Investigator accordance protocol requirement taper washout . 18 . Are unable understand protocol requirement , instruction study relate restriction , nature , scope possible consequence clinical study . 19 . Are unlikely comply protocol requirement , instruction study relate restriction ( eg , uncooperative attitude , inability return outpatient visit improbability complete clinical study ) . 20 . Are unable tolerate Oral Risperidone Challenge</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>